BeyondSpring (BYSI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual general meeting is scheduled for September 15, 2025, with both in-person and virtual participation options available.
Shareholders will vote on the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The board of directors unanimously recommends voting in favor of the ratification proposal.
Only shareholders of record as of July 25, 2025, are entitled to vote at the meeting.
Voting matters and shareholder proposals
The main proposal is the ratification of CBIZ CPAs P.C. as the independent auditor for 2025.
Any other matters that properly come before the AGM may also be voted on.
Shareholders holding at least 10% of voting share capital can requisition an extraordinary general meeting.
Proposals for the 2026 AGM must be received by April 8, 2026, for inclusion in proxy materials.
Director nomination notices for the 2026 AGM must be received by July 17, 2026.
Board of directors and corporate governance
The audit committee is responsible for the appointment, compensation, and oversight of the independent auditors.
The board solicits proxies and recommends voting in favor of the auditor ratification.
Latest events from BeyondSpring
- Plinabulin achieved Phase 3 survival benefit in NSCLC; financials strengthened and pipeline advanced.BYSI
Q4 202525 Mar 2026 - Biopharma firm registers 10M shares for R&D and corporate use, facing clinical and financial risks.BYSI
Registration Filing16 Dec 2025 - Up to 10M shares registered for flexible sale to fund R&D amid ongoing financial uncertainty.BYSI
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification at the September 2025 annual meeting.BYSI
Proxy Filing2 Dec 2025 - Net loss narrowed, Plinabulin advanced in NSCLC, SEED divested and raised $30M, cash at $12.5M.BYSI
Q3 202512 Nov 2025 - Q2 2025 saw narrowed net loss, SEED divestiture progress, and clinical advances in oncology.BYSI
Q2 202513 Aug 2025 - Plinabulin and SEED's TPD platform deliver clinical and pipeline breakthroughs with strong pharma alliances.BYSI
Corporate Presentation4 Jul 2025 - Net loss narrowed and cash improved, but shareholder's deficit remains substantial.BYSI
Q2 202413 Jun 2025 - Q1 2025 net income rose to $4.5M from SEED sale; Plinabulin advanced in cancer trials.BYSI
Q1 20256 Jun 2025